First patient trials for lung cancer vaccine starts. A lung cancer patient in the UK has become one of the first to participate in a groundbreaking trial for the world's first vaccine against the disease. The vaccine, known as BNT116 and developed by BioNTech, utilises messenger RNA (mRNA) technology to help the immune system recognise and attack cancer cells. The world-first jab is designed to target non-small cell lung cancer (NSCLC), which makes up 85 percent of all lung cancer cases. It works by presenting the patient’s immune system with information about common tumour markers associated with NSCLC. This specific targeting aims to destroy cancer cells while minimising damage to healthy cells, in contrast to the effects of chemotherapy. This ground-breaking study will involve about 130 patients with various stages of NSCLC, ranging from early stages before surgery or radiotherapy to late-stage disease, across 34 research sites in seven countries. As well as the UK, the trial is being rolled out in four other European countries - Germany, Spain, Poland, and Hungary - as well as the United States and Turkey. Thousands of patients are expected to take part in follow-up trials over the next few years.